Paul Tudor Jones’s CytomX Therapeutics CTMX Stock Holding History

Paul Tudor Jones’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.18M	Buy	+1,380,687	New	+$5.27M	0.01%	1257
2024 Q2	–	Sell	-43,865	Closed	-$95.6K	–	2393
2024 Q1	$95.6K	Sell	43,865 -865	-2%	-$1.6K	﹤0.01%	2095
2023 Q4	$69.3K	Hold	44,730	–	–	﹤0.01%	2258
2023 Q3	$57.7K	Hold	44,730	–	–	﹤0.01%	2173
2023 Q2	$76.9K	Hold	44,730	–	–	﹤0.01%	2310
2023 Q1	$68K	Sell	44,730 -118,267	-73%	-$267K	﹤0.01%	2275
2022 Q4	$261K	Hold	162,997	–	–	0.01%	1997
2022 Q3	$236K	Hold	162,997	–	–	0.01%	1955
2022 Q2	$298K	Hold	162,997	–	–	0.01%	1566
2022 Q1	$435K	Buy	+162,997	New	+$626K	0.01%	1348
2021 Q1	–	Sell	-51,873	Closed	-$340K	–	1607
2020 Q4	$340K	Sell	51,873 -47,068	-48%	-$336K	0.01%	1081
2020 Q3	$658K	Buy	98,941 +74,370	+303%	+$552K	0.03%	717
2020 Q2	$205K	Sell	24,571 -18,720	-43%	-$174K	0.01%	1021
2020 Q1	$332K	Sell	43,291 -35,488	-45%	-$247K	0.03%	655
2019 Q4	$655K	Buy	+78,779	New	+$532K	0.03%	639

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Paul Tudor Jones's CTMX Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 1,380,687 shares worth $5.18M. The stake represents 0.01% of the portfolio and ranks #1257 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in CTMX as recently as Q1 2024.

Paul Tudor Jones first reported a position in CTMX in Q4 2019 and has held it in 15 quarters since. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Paul Tudor Jones held 1,380,687 shares of CytomX Therapeutics worth $5.18M as of Q2 2026.
CytomX Therapeutics was a new Paul Tudor Jones position in Q2 2026.
CytomX Therapeutics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1257 holding.
Paul Tudor Jones first reported a position in CytomX Therapeutics in Q4 2019 and has held it in 15 quarters since.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.